As shown in Figure 5E, hUC‐MSCs treatment decreased IL‐17 concentration in the supernatant compared with the SLE‐MS group (10,983 ± 1013.16 vs. 13,554.33 ± 482.53 pg/mL; p < 0.05). This evidence concerns the gene IL17A and systemic lupus erythematosus.